Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Sage Therapeutics, Inc. is a biopharmaceutical company ... The company has strategic collaborations with Biogen and Shionogi & Co., Ltd. to develop and commercialize its products in various global ...

Sage Therapeutics Inc. leadership overhyped prospects for three neurological and psychiatric treatments, harming the biopharmaceutical company’s repute and wallet, a shareholder lawsuit said.

Access our full analysis report here, it’s free. Therapeutics company Biogen (NASDAQ:BIIB) jumped 5.1%. Is now the time to buy Biogen? Access our full analysis report here, it’s free.

Is now the time to buy Thermo Fisher? Access our full analysis report here, it’s free. Therapeutics company Biogen (NASDAQ:BIIB) jumped 5.1%. Is now the time to buy Biogen? Access our full analysis ...

CRISPR Therapeutics has begun realizing sales on Casgevy, its first therapy and a joint venture with Vertex Pharmaceuticals. The company has plenty of cash to fund research and development for the ...

Our free stock report includes 3 warning signs investors should be aware of before investing in Nektar Therapeutics. Read for free now. Revenue missed analyst estimates by 32%. Earnings per share ...

The analysis below examines the analyst ratings and average 1-year price targets of Sage Therapeutics, Precigen and Organogenesis Holdings, three significant industry players, providing valuable ...